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ABSTRACT 
 
BACKGROUND: Periodontal disease is a chronic inflammatory disease resulting in 
destruction of tooth supporting apparatus. Although the disease is microbial in origin 
destruction of hard and soft tissues of periodontium occurs as an exaggerated host 
response. 50% variation in inflammatory response/cytokine production is thought to 
be related to genetic factors such that genetic risk markers are now recognized as 
important risk determinants of periodontal disease.                         
  IL -18  is a pleiotrophic cytokine with multiple biological activities involved 
in regulation of both the innate and the aquired immune responses through various 
biological pathways. The interleukin -18 molecule shares its structural homogeneity 
with interleukin 1 receptor family, TNF-α. Interleukin -18 plays a role in periodontal 
disease susceptibility, initiation and progression through the Th1/Th2 cytokine 
profile. 
AIM:   The aim of the study is to the distribution of single nucleotide 
polymorphism, in promoter region -607 C-A of IL-18 coding region, in the study 
population and to correlate the association of single nucleotide polymorphism (SNP) 
in promoter region -607 C-A of IL-18 coding region with chronic periodontitis. 
MATERIALS AND METHODS: Genomic DNA was obtained from peripheral 
blood samples in 100  periodontally healthy subjects (control group), 100 subjects 
with  generalized chronic periodontitis (study group ) and  promoter region -607 C-A 
of IL-18 coding region   was amplified by polymerase chain reaction, and the 
polymorphism was analyzed by restriction endonuclease cleavage. The alleles were 
detected by agarose gel electrophoresis and visualised with ethidium bromide. 
RESULTS:The percentage distribution of allele frequency for A and C allele among 
control and study group is statistically insignificant as the p values is greater than 0.05 
(p value 0.932). Also the distribution of genotypes for the IL-18 gene polymorphism 
at position-607 among the control study group is insignificant whose p value is 0.854. 
CONCLUSION: Susceptibility for periodontitis is not influenced by the SNP at -
607of IL 18 gene that have been investigated in this study and we find no association 
between them. 
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INTRODUCTION 
 
Chronic periodontitis is a complex multifactorial disease in which host genetic 
makeup can modify the course rather than cause it outright77.  Its aetiology consists of 
the interplay between anaerobic bacteria found in the biofilm, subgingival dental 
plaque and exaggerated immune responses in susceptible individuals95.  Each person 
has an individual dose–response curve that defines host susceptibility to             
periodontitis 65,66. 
 
 Certain patients are disease-resistant and show no disease progression beyond 
gingivitis or early periodontitis. This emphasizes the predominant role of host 
response, rather than bacterial etiology, as the principal determinant of disease 
expression.  
 
Cytokines play a vital role in the pathogenesis of  many of diseases including 
periodontal disease 71.  Today, vast number of available scientific articles supports the 
indispensable role of genes in the initiation and progression of periodontal disease by 
altering the immune responses at various levels. Specifically, different allelic variants 
can result in variations in tissue structure (innate immunity), antibody responses 
(adaptive immunity), and inflammatory mediators (non-specific inflammation)42,95 
which could act as protective or risk factors for periodontitis61, For this reason, 
periodontitis is considered as a complex genetic disease whose phenotype is 
determined by both the genetic makeup and the environmental influences on the 
affected individual.  
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The twin study design, the most popular and a reliable tool in genetics 
supports the involvement of genetic components of a disease. This also substantiates 
the contribution that genes make vs. the environment in a phenotypic expression. 
Based on twin study design Adult periodontitis was estimated to have 50% 
heritability, which was unaltered following adjustments for behavioural variables  
including smoking. It was concluded that there is indeed a substantial genetic basis for 
the risk of chronic periodontitis55. 
 
 Currently, the presence of interleukin genetic variations appears to identify 
individuals who are at increased risk for more severe chronic periodontitis and for a 
less predictable response to therapy.  
 
In 1997, Kornman et al45  described a composite genotype formed by the two 
polymorphic loci – interleukin-1A 889) and interleukin-1B (+3953) – single 
nucleotide polymorphisms that carry a C–T transition. This was later known as 
periodontitis-associated genotype. 
 
 IL-18 is a proinflammatory and tumor-suppressive cytokine, which due to its 
structure, receptor family and signal transduction pathways belongs to the IL-1 
cytokine family 9,58. It is unique, with the capacity to induce either Th1 or Th2 
differentiation depending on the immunological context59. In the presence of IL-12, 
IL-18 induces Th1 responses while in the absence of IL-12, it promotes Th2 
responses. It is clear, therefore, that IL-18 has the ability to induce either Th1 or Th2 
differentiation. It is logical to hypothesize, SNPs in IL-18 coding region may 
modulate the diseases process. 
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Recently six different polymorphisms within the IL-18 gene have been 
identified. Three Single Nucleotide Polymorphisms (SNPs) were found in the 
promoter region (-656 G/T; -607 C/A, -137 G/C) and two of the polymorphisms were 
observed in the 50-untranslated region (1113 T/G, 1127 C/T)28.  Moreover, one 
polymorphism was found in the coding region of the IL-18 gene at position 10532. 
Although the functional significance of the aforementioned polymorphisms is yet not 
fully established it was suggested that particularly the polymorphisms at position -607 
and -137 are associated with considerable changes in IL-18 expression28,85.  
 
Functional effective polymorphisms in genes coding for cytokines that are 
involved in the regulation of the inflammatory process are attractive candidates to 
delineate the genetic background of periodontitis. Based on this rationale, the present 
study aimed to assess whether polymorphisms of the IL-18 gene contribute to the pre-
disposition to periodontitis and the distribution of genotypes among patients with 
periodontitis and healthy controls. 
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AIM AND OBJECTIVE 
 To study the distribution of single nucleotide polymorphism, in promoter 
region -607 C-A of IL-18 coding region, in the study population. 
 To correlate the association of single nucleotide polymorphism (SNP) in 
promoter region -607 C-A of IL-18 coding region with generalized chronic 
periodontitis. 
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REVIEW OF LITERATURE 
 
Cytokines an Overview 
Cytokines are central to the pathogenesis of an ever-increasing number of 
diseases, including periodontal disease. They are inter-cellular messengers and, as 
such, represent a key mechanism by which cells involved in immune responses 
communicate. Numerous cytokines are produced in response to microbes and other 
antigens and stimulate diverse responses.  Cytokines interact in a network by inducing 
each other, transmodulating cell-surface receptors, and by synergistic, additive, or 
antagonistic interactions on cell function7. 
 
Cells that produce cytokines include the macrophages/monocytes, dendritic 
cells, lymphocytes, neutrophils, endothelial cells, and fibroblasts1.  
 
In immune regulation of periodontal disease cytokines are usually produced 
transiently, often in picomolar concentrations. Indeed, the majorities of immune 
responses occur locally, and often between two cells conjugated together. In other 
situations, however, large amounts of cytokine are produced, which allows cells to 
communicate at a distance. Such cytokines include IL-1 and IL-6, which are produced 
by a large number of cells and in relatively large quantities79. 
 
Gemmell and Seymour 200425 Postulated that "appropriate" cytokine 
production results in protective immunity, while "inappropriate" cytokine production 
leads to tissue destruction and disease progression. 
 
6 
 
Cytokines and T Cell Subtypes 
  Several cytokines are involved in Th1 immune responses. These include: IL-
12, IL-18, IFN- γ and tumor necrosis factor (TNF) α .In contrast, IL-4, IL-5, and IL-
13 are involved in Th2 immune responses and promote humoral immunity by 
promoting B-cell growth and differentiation8,57.   
 
O'Garra, 199867 established the induction role of cytokines in the 
development of heterogenous T cell subsets and tremendous built-in redundancy of 
cytokines, such that many cytokines have overlapping functions. He also postulated 
that equally, many cytokines are antagonistic, and, again, the overall biological effect 
is the result of the balance between all cytokines, rather than their individual levels. 
The balance between cellular and humoral responses, for example, is strongly 
regulated by the balance between Th1 and Th2 subsets .Th1 cells are characterized by 
their production of interferon-γ (IFN-γ) and are responsible for directing cell-
mediated immune responses leading to the eradication of intracellular pathogens, but 
may also cause immunopathology and organ-specific autoimmune disease if 
deregulated. 
 
Interleukin 18-An Overview    
IL-18 was first discovered in 1995 and was originally identified as interferon-γ 
(IFN-γ)-inducing factor68. 
 
Nakanishi et al., 2001a59 reported that IL- 18 is unique, with the capacity to 
induce either Th1 or Th2 differentiation, depending on the immunological context  
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IL-18 is a proinflammatory and tumor-suppressive cytokine, which, due to its 
structure, receptor family, and signal transduction pathways, belongs to the IL-1 
cytokine family9,58. 
  
Locus of IL- 18 Gene and Structure 
The human IL-18 gene is located on chromosome 11q22; the synthesized 
protein contains 193 amino acids and shares 64% identity with its mouse homologue  
structure of IL-1863. 
 
Biet et al., 20029 reported that IL -18 display structural similarities although 
shares less than 30% primary amino acid sequence homology with the IL-1 family 
members—(IL-1α, IL-1βand IL- 1 receptor antagonist (IL-1Ra) 
 
Li et al., 200349 stated that while IL-1 and IL-18 and their receptors are 
members of the IL-1 family, there are several biological and functional differences 
among them. One of these is that IL-18 induces IFN-γ from T-cells and NK cells,            
but does not cause fever, whereas induction of fever is a well-known characteristic of 
IL-1.  
 
Kato et al. 200340 using MNR spectroscopy, have described the IL-18 
structure. Its overall structure is well defined, except the segment between residues 34 
and 43. IL-18 consists of 12 strands that form 3 twisted four-stranded β sheets, with 
one short α helix and one 310-helix. The three β sheets are packed against each other, 
to adopt a β trefoil fold, which is similar to those of IL-1β, but the surface residues are 
totally dissimilar. The loop, residues 32-42, spreads out from the body of the protein 
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and seems to be flexible.  He further described 3 sites important for receptor 
activation: two sites that serve as binding sites for IL-18R (α) and the third for binding 
to IL-18R (β). 
                                                                                                                                       
IL -18 Synthesis:  
Similar to IL-1β, IL-18 is intracellularly synthesized as a 24-kDa biologically 
inactive precursor (pro-IL-18)9,17,18,19,27,31,69 and is secreted as an 18-kDa inactive 
form requiring caspase-1 (ICE) (which is the same enzyme that cleaves pro- IL-1β IL-
1β-converting enzyme), to cleave it into the active IL-18 molecule88.  
 
Nakanishi et al., 2001b60 suggested that this process could occur after Toll-
like receptor-4 (TLR-4) is activated by lipopolysaccharide (LPS), or, alternatively, 
upon stimulation with FasL, a caspase other than ICE, termed 'casp1-like', which 
might be activated to cleave the pro-IL-18 into active IL-18. 
 
IL-18 Receptor: Characteristics, Expression and Activation 
 Parnet et al., 199674 reported  IL-18R to be selectively expressed on Th1, but 
not Th2, cells, and was proposed to be considered as a cell-surface marker to 
distinguish Th1 from Th2 cells  
 
Born et al., 199812  IL-18 shares structural organization with the IL-1R/Toll-
like receptor (TLR) super family. The IL-18 receptor (IL-18RC) complex consists of 
2 receptor chains: the ligand -binding IL-18Rα chain, originally identified as IL-1 
receptor-related protein (IL-1Rrp), and the core-receptor IL-18Rβchain, formerly 
designated as accessory-protein-like (IL-18AcPL). Both chains are required for 
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signaling. The activity of IL-18 begins with its binding to the IL-18RC. IL-18Rα 
binds IL-18 with low affinity, whereas IL-18Rβ does not bind IL-18, but increases the 
affinity of the receptor and participates in signal transduction  
 
Sigal, 200580. IL-18 receptor (IL-18R) is found on T-cells, NK cells, B cells, 
and dendritic cells. 
 
The mechanism by which the formation of the IL-18RC leads to intracellular 
signal transduction is as follows the recognition of glycosylphosphatidylinositol (GPI) 
anchor glycans by IL-18 and IL-18Rα induces formation of the IL-18/IL-18Rα 
CD48/GPI anchor glycan complex, and this complex and the specific peptide 
sequences trigger binding to IL-18Rβ and induce intracellular signal transduction23.                         
    
Intra Cellular Signaling by IL-18 
Following activation of pro-IL-18, active IL-18 mediates IL-18R aggregation, 
after which the heterodimeric complex recruits the adaptator molecule MyD88, as 
well as IL-1 receptor-associated kinase (IRAK). After phosphorylation, IRAK 
dissociates from the receptor complex and then associates with TNF receptor-
associated factor 6 (TRAF6), which leads to the sequential activation of NF-κB 
binding kinase (NIK), I-κB kinases (IKK-1, IKK-2). This leads to the release of the 
NF-κB subunits p65/p50 from I-κB, and their translocation to the nuclear κB binding 
sites. Alternatively, the binding of IL-18 triggers the activation of Ras, resulting in an 
activation cascade of Raf, mitogen-activated extracellular signal-regulated kinase-
activating kinase (MEK), and mitogen activated protein kinase (MAPK). This induces 
phosphorylation of MAPK. After phosphorylation, MAPK is translocated into the 
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nucleus and phosphorylates NF-IL6, which allows NF-IL6 to associate to the C/ERP 
binding site9,17,39,60,76. 
 
In epithelial cells, IL-18 transduction is primarily via the MAPK p38 pathway, 
rather than NF-κB, which may explain the absence of cyclo-oxygenase (COX)-2 and 
the inability of IL-18 to cause fever47.  
 
Biological Activities of IL- 18: 
Although Th2 cells expressing IL-18R have been reported86, they cannot 
produce IFN-γ in response to anti-CD-3 and IL-18, whereas functional IL-18R is 
selectively expressed on Th1 and shows a strong capacity to produce IFN-γ in 
response to anti-CD-3 plus IL-18 or IL-1β.  
 
Reported that IL-18 synergizes with IL-12 to induce IFN-γ production from 
natural killer (NK) and T-cells and, therefore, Th1 cell development, but does not 
depend on IL-12 for its activity9,52,60,68. 
 
Chang et al., 200015 reported that IL-18, in the absence of IL-12, induces the 
production of Th2 cytokines from T-cells, NK cells, and also basophils/mast cells60. 
However, large amounts of IFN-γ, as well as IL-12Rα expression on T-cells are 
induced in response to IL-12 and IL-18 .Therefore, IL-18 stimulates either Th1 or Th2 
responses, depending on its local cytokine milieu. 
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While IL-12 and IL-18 play a major role in IFN-γ induction, it has also been 
shown that PGE2 has the capability to antagonize the potent inductive signal provided 
by the combination of IL-12 and IL-18.   Physiological concentrations of PGE2 
significantly suppressed NK cell IFN-γ synthesis, regardless of cytokine stimulation. 
PGE2 may thus play an important role in limiting the innate and adaptive immune 
processes through direct suppression of NK cell IFN-γ synthesis89.  
 
In addition to the above, IL-18 also  plays an important role in the activation 
of non-T-cell populations, such as macrophages, neutrophils, endothelial cells, 
synovial fibroblasts, chondrocytes, osteoclasts, and keratinocytes35,48,50,60. 
 
Chemotaxis of human NK cells is enhanced by IL-18, which also induces the 
production of activated MMP-2 and pro-MMP-2, as well as MT1-MMP, from NK 
cells36. 
 
With regard to the B-cells, it has been found that human B cell lines 
ubiquitously express mRNA for IL-18, IL-18Rα, and IL-18Rβ, but do not secrete IL-
18 protein; hence, IL-18 possibly affects B-cells through paracrine actions, and it may 
well be that B-cells may be passive bystanders with an innate ability to use IL-1851.  
 
IL-18  promotes  Fas-dependent apoptosis of endothelial cells, hepatocytes, 
and basophils14,20,78. 
 
Keratinocytes responded to IL-18 with an up-regulation of the major 
histocompatibility complex (MHC) class I and II expression, and production of the 
chemokine CXCL10, suggesting that IL-18 may also contribute to the chronicity of 
inflammatory skin diseases90.         
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IL-18 In Infections and Systemic Diseases: 
Bohn et al., 199811 demonstrated the inhibition of IL-18 production with the 
use of anti-IL-18 antibodies  which lead to uncontrolled bacterial infections. The 
central role of IL-18 in the development of protective immunity against bacterial 
infections is well-established. 
 
Fujioka et al., 199922 have shown in   invitro experiments that IL-18 also has 
protective properties against several viruses.  
 
There have been several reports relating the up-regulation of IL-18 to human 
inflammatory and autoimmune diseases, including rheumatoid arthritis93, psoriasis44, 
type I diabetes62, atherosclerosis53, and chronic heart failure/coronary heart 
disease10,95.  
 
Periodontitis and rheumatoid arthritis are chronic inflammatory disorders that 
share similar biological mechanisms of tissue destruction. Persons with rheumatoid 
arthritis display a poorer periodontal status54.  
 
An incipient attachment loss has been reported56  more frequently in those 
with juvenile idiopathic arthritis (JIA) than in control individuals, despite having 
similar amounts of plaque and marginal bleeding .This study examined neutrophils 
activity and proinflammatory cytokines in the two groups, and found significantly 
elevated serum levels of IL-1β and IL-18 in the JIA group. When the JIA group was 
subdivided according to the presence or absence of attachment loss, IL-18 was 
significantly increased in the subgroup with attachment loss. 
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IL 18 and AIDS 
Pages et al., 200573 has demonstrated that the Epstein-Barr virus nuclear 
antigen (EBNA2) can induce the expression of the IL-18 receptor (IL-18R), both in 
Burkitt lymphoma and in non transformed B-cell lines, allowing the infected cells to 
respond to IL-18. EBNA2 expression has also been associated with IL-18R 
expression in vivo in EBV-positive B lymphomas from persons with AIDS  
 
IL-18 And Periodontal Diseases 
In addition to its capacity to act as a potent co-stimulus for Th1 induction, and 
its ability to induce TNF-α and IL-1β in mononuclear cells, IL-18 is able to initiate a 
cytokine cascade with a concomitant increased expression of pro-inflammatory 
markers, such as chemokines, nitric oxide, adhesion molecules, and MMP-943,64. 
 
Xu et al., 199891 reported IL-18 together with IL-12, in much lower 
concentrations, had an increased effect on reducing bone-resorbing activity, whereas 
IL-12 alone had no significant effect. This synergistic effect could be due to the fact 
that IL-12 increases the responsiveness to IL-18 via an increase in IL-18 receptor 
expression. 
 
Yamada et al. 200292 investigated the in vitro effect of IL-18 on osteoclastic 
bone resorbing activity, and found that when different concentrations of IL-18 were 
applied to osteoclast-enriched cell cultures, bone resorbing activity decreased. 
 Also, the combination of the two cytokines ,IL-18&IL-12 synergistically 
increased the concentrations of IFN-γ, suggesting the importance of IFN- γ in the 
inhibition of osteoclastic bone resorbing activity. 
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Grandjean-Laquerriere et al. 200429 investigated the ability of HA particles 
to induce production of active IL-18 by human monocytes. They used 10 HA-based 
powders that differed in size range, shape, and surface area, and demonstrated that 
HA particles can trigger IL-18 production in human monocytes. The parameter that 
demonstrated the greatest influence on the cells proved to be shape. The most 
significant production of IL- 18 was observed when cells were exposed to needle-
shaped particles 
  
Johnson and Serio 200538 have reported on the concentrations of IL-2, IL-4, 
IL-6, IL-10, IL-12, IL-18, and IFN-γ in the gingival tissues of Dominican Republic 
Hispanic individuals with healthy and diseased periodontium. Diseased periodontal 
tissues displaying bleeding on probing were subdivided into 3, 4 to 6, and > 6 mm 
probing depths. Concentrations of all the cytokines adjacent to 4-6-mm diseased sites 
were greater than in healthy sites, where IL-12 concentrations were higher. 
 
Johnson and Serio, 200538 have reported IL-6 and IL-18 concentrations were 
greater adjacent   to > 6 mm sites compared with healthy sites. IL-6 and IL-18  
positively correlated with deep probing depths, while IFN-γ and IL-12 demonstrated 
negative correlations. It was suggested that IL-18 and IL-6 accumulate within the 
gingiva, possibly contributing to a non-resolving hyper-inflammation mediated by a 
shift toward a Th2 phenotype. 
 
Orozco et al., 200670 suggested that the local production of IL-1β and IL-18 in 
the gingival crevicular fluid increased with increasing inflammation, and IL-18 was 
the predominant cytokine at both gingivitis and periodontitis sites. Very little IL-12 
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was detected, with levels decreasing with increasing inflammation. Therefore, it was 
suggested that there is an association between the severity of periodontal disease and 
IL-1, IL-12, and IL-18 levels.  
 
Recently Pradeep A.R et al 200975  has researched wherein sixty subjects (30 
males and 30 females; age range: 26 to 49 years) participated in the study. The 
subjects were initially divided into three groups, consisting of 20 subjects in each 
group, based on the gingival index, probing depth (PD), clinical attachment loss (AL), 
and radiologic parameters (bone loss): healthy (group 1), gingivitis (group 2), and 
periodontitis (group 3), patients in group 3 after treatment constituted group 4. GCF 
samples were collected from all of the groups to estimate the levels of IL-18 and 
MCP-1 using enzyme-linked immunosorbent assay. In the result the mean IL-18 and 
MCP-1 concentrations in GCF were highest in group 3 (330.61 pg/ml and 73.3 pg/ml, 
respectively). The results suggest that IL-18 and MCP-1 levels increased in GCF from 
periodontal health to disease and decreased after periodontal therapy. Levels of IL-18 
and MCP-1 positively correlated with PD and clinical AL in group 3. In addition, IL-
18 and MCP-1 levels significantly correlated with each other in groups 2, 3, and 4. 
The results were GCF IL-18 and MCP-1 concentrations increased in periodontal 
disease compared to health and correlated positively with the severity of disease. 
Further, based on the positive correlation of IL-18 and MCP-1  in this study, they 
reported that IL -18 may promote an inflammatory response by the induction of MCP-
1 production and the subsequent recruitment and activation of circulating leukocytes 
at the inflammatory site. 
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Genetic Polymorphisms 
Genetic polymorphisms have historically been used as genetic markers to 
locate disease-causing genes through linkage studies. By definition, a genetic 
polymorphism is a nucleotide sequence at a particular position in DNA molecules 
exhibiting at least two structural variants (alleles) that occur in the population at a 
frequency of greater than 1%. There are a number of different types of nucleotide 
structure in the human genome that fit this definition. 
• Variable Number of Tandem Repeats (VNTR) 
• Microsatellite Polymorphism 
• Single Nucleotide Polymorphism (SNP) 
 
A single nucleotide polymorphism (SNP)5 is a variation in the identity of a 
single nucleotide at a particular site in the genome.  The SNP defines two alleles for 
which there could be three genotypes amongst individuals in a given population. 
SNPs include, but are not limited to, restriction fragment length polymorphisms 
(RFLPs), i.e. nucleotide changes that create or destroy sites for restriction 
endonucleases in the DNA molecule. 
 
Michalowicz et al 199155 reported the periodontal condition of 110 pairs of 
twins from 16 to 70 years old. The mean probing depth and attachment level scores 
were found to vary less in MZ twins reared together than in DZ twins reared together. 
In a subsequent related study of 64 MZ and 53 DZ adult twin pairs, Michalowicz and 
co-workers estimated the genetic and environmental variances and heritability in CP 
according to path models with maximum likelihood estimation techniques. MZ twins 
were found to be more similar than DZ twins for all clinical measures. Statistically 
significant genetic variance was found for both the severity and extent of disease. 
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Adult periodontitis was estimated to have approximately 50% heritability, which was 
unaltered following adjustments for behavioural variables including smoking.  
 
 Kornman et al 199745 reported the correlation between genetic 
polymorphisms and Chronic Periodontitis undertaken by the IL-1 gene. The combined 
presence of the R allele in the IL-1α gene at nucleotide position-889 and the R-allele 
of IL-1α gene at nucleotide position +3953 were associated with severity of 
periodontitis in non-smoking Caucasian patients.  
 
Giedraitis et al. 200128  identified five different polymorphisms within the IL-
18 gene (promoter region and untranslated region). Three single nucleotide 
polymorphisms (SNPs) were found in the promoter region (-656 G/T; -607 C/A, -137 
G/C) and two of the polymorphisms were observed in the 50-untranslated region 
(1113 T/G, 1127 C/T) Moreover, one polymorphism was found in the coding region 
of the IL-18 gene at position 10532.  
 
The human IL-18 promoter gene cloned and screened for possible 
polymorphisms. Three single nucleotide polymorphisms were detected in the 
promoter and two polymorphisms in the 59-nontranslated region of the gene. Three 
combinations of these polymorphisms were observed in the Swedish population. All 
IL-18 promoter alleles were found to have clear promoter activity when inserted into 
a luciferase reporter vector. There were no significant differences in promoter activity 
between alleles without stimulation, but after stimulation with PMA/ionomicin one of 
the alleles had clearly lower activity than the other (P 0.01). Measurement of IL-18 
and IFN-γ production in 48 multiple sclerosis patients by RT-PCR showed slightly 
higher expression of IL-18 in individuals homozygous for the most frequent 
haplotype. Two IL-18 promoter polymorphisms were analyzed by sequence specific 
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PCR in 208 multiple sclerosis patients and 139 healthy controls, however, no 
significant differences were found. The data indicates that common IL-18 promoter 
polymorphisms influence the expression of IL-18 and potentially also of IFN-γ 
suggested in their mutation analysis  experiments, Although the functional 
significance of the aforementioned polymorphisms is yet not fully established, the 
polymorphisms at position -607 and -137 are associated with considerable changes in 
IL-18 expression28,86. 
 
 Folwaczny M et al 200521 reported a total of 123 patients with periodontitis 
and 121 healthy controls were genotyped for six IL-18 polymorphisms at position -
656, -607, -137, 1113, 1127 and codon 35/3.  In their study genotyping was 
performed by PCR and restriction fragment length polymorphism analysis. The 
frequencies of alleles and genotypes as well as haplotypes within both study groups 
were compared using the Pearson Chi-square test at a level of significance of 5%           
(p-0.05).  Coseggregation was found to be 100% for the two polymorphisms at 
position -656 and -607 as well as for the polymorphisms at position -137, 1113, and 
1127. The distribution of genotypes for the IL-18 gene polymorphism at position -
656/-607 (p50.854), at position -137/1113/1127 (p50.320), and at codon 35/3 
(p50.481) was not significantly different among periodontitis patients if compared 
with healthy control subjects. The distribution of haplotype combinations for the -607 
and -137 polymorphism also showed not significant difference between the both study 
groups (p50.545).They concluded that those six different IL-18 gene polymorphisms 
were not associated with destructive periodontal disease. 
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MATERIALS AND METHOD 
STUDY DESIGN AND SUBJECT SELECTION: 
 
After  passing ethical clearance to conduct the research, around 200  patients  
in  the  age group  of  30- 70  years who  attended  the  outpatient  wing of  
Department of Periodontology, Tamilnadu Government Dental College, Chennai  
during March to December of 2010  participated  in the  study . The patients  were 
divided  into  2  groups,  100 subjects  with  generalized chronic periodontitis and 100  
periodontally healthy subjects    as study and control group respectively. All were 
Tamil speaking Dravidians. 
A   written informed consent was obtained from all   patients.    A complete  
medical, dental history and  the following  periodontal parameters , plaque  index, 
gingival  bleeding index, probing  depth,  clinical  attachment  loss  were  recorded 
and their ethnic origin was confirmed from their oral history. 
 About  5 ml of  venous  blood samples  were  collected  from  the  patients 
with  or without  periodontitis  for analyzing their genotypic status and to find the 
distribution of C-A single nucleotide polymorphism at -607 position of IL-18 
promoter region. 
 
Inclusion Criteria: 
1.  Subjects above or equal to 35 years of age were included for study group and 
above or equal to 30 years were included for control group. 
2. Includes both the gender. 
3. Selected samples were the ethnic origin of Tamil speaking Dravidians. 
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Exclusion criteria: 
1. Diabetes or Immunodeficiency syndromes 
2. Any disease known to compromise immune function 
3. Periodontal treatment within past 6 months 
4. Pregnancy or Lactation 
5. Premedication for dental treatment 
6. Non-steroidal anti-inflammatory drugs in the past three years 
7. Immunosuppressive chemotherapy 
8. Presence of any acute infection 
The subjects selected for the study were divided into two groups, control 
group  and study group  of one hundred each based on the above said criteria. 
CONTROL GROUP: (Healthy Periodontium): 
 Control group included 100 subjects with clinically healthy periodontium. 
Subjects found to exhibit no signs of periodontal disease as determined by the absence 
of clinical attachment loss and no sites with probing pocket depth >3 mm4.  
 
STUDY GROUP: (Generalised  Chronic Periodontitis): 
  Study group included 100 subjects (smokers included) with clinical 
attachment loss ≥1mm4 involving > 30% of total numbers of sites examined13.  
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STUDY PROTOCOL 
1. Obtaining approval from Institutional ethical committee. 
2. Sample selection by applying inclusion and exclusion criteria  
3. Obtaining informed consent  
4.  Documenting the clinical parameters namely gingival bleeding index, 
plaque index, probing pocket depth and clinical attachment level. 
5. Collection of blood sample 
6. DNA isolation and purification 
7. Quality check of DNA 
8. Polymerase chain reaction 
9. Restriction fragment length polymorphism to detect the genotype 
10. Statistical analysis 
11. Data interpretation. 
Following selection of subjects, informed consent was obtained from all the 
subjects selected for the study after explaining the study procedure verbally. 
Examination was preceded by a thorough medical and dental history of the subjects. 
Intra-oral examination was done using mouth mirror and Williams periodontal 
probe. Periodontal evaluation was done by measuring the gingival bleeding index, 
plaque index, probing pocket depth (PPD) and clinical attachment level (CAL). 
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Clinical Parameters: 
Gingival Bleeding index3 (GBI) 
Teeth examined - All teeth 
Surfaces examined - 4 sites for each tooth (Mesial, buccal, distal, palatal) 
 
  The presence or absence of bleeding is determined by gentle probing of the 
gingival crevice with a periodontal probe 
 
Criteria for Scoring: 
Positive score (+) - Presence of bleeding on probing within 20 seconds 
Negative score (-) - Absence of bleeding on probing within 20 seconds 
 
    Total number of positive score 
% of bleeding sites =            x 100 
    Total number of surfaces of all teeth   
 
PLAQUE INDEX81 (PlI) 
Surfaces Examined  
 Distofacial, facial, mesiofacial, lingual 
Criteria for scoring 
Score 0 : No plaque 
Score 1 : Film of plaque at marginal area recognized by running a probe 
Score 2  : Moderate accumulations as can be seen by naked eye 
Score 3 : Abundance of soft matter 
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Calculation 
Plaque Index (PI) per tooth   = Total of score 
      4 
  
PI per individual  = Total of PI per tooth 
             Total no. of teeth examined 
Interpretation  
 0  -  Excellent  
 0.1 – 0.9 - Good 
 1.0 – 1.9 - Fair 
 2.0 – 3.0 - Poor 
 
Probing Pocket Depth (PPD)30  
Probing pocket depth is measured from the gingival margin to the base of the 
pocket using William periodontal probe. The probe is passed under the gingiva along 
the circumference of the tooth. Three measurements are made on the buccal aspect 
and three on the lingual aspect of each tooth-total of six sites per tooth (Mesiobuccal, 
Midbuccal, Distobuccal, Mesiolingual, Midlingual and Distolingual). 
 
Clinical Attachment Level (CAL)13 
Clinical attachment level is measured from the cementoenamel junction to the 
base of the pocket using Williams periodontal probe.  When the gingival margin is 
located on the anatomic crown, the level of the attachment is determined by 
subtracting from the probing pocket depth, the distance from the gingival margin to 
the cementoenamel junction. If both are the same, the loss of attachment is zero. 
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When the gingival margin coincides with the cementoenamel junction, the loss of 
attachment equals the probing pocket depth. When the gingival margin is located 
apical to the cementoenamel junction, the loss of attachment is greater than the 
probing pocket depth and therefore the distance between the cementoenamel junction 
and the gingival margin should be added to the probing pocket depth. 
 
Three measurements were made on the buccal aspect and three on the lingual 
aspect of each tooth – total of six sites per tooth ( Mesiobuccal , Midbuccal, 
Distobuccal, Mesiolingual, Midlingual and Distolingual).From the recorded data 
Samples that involved  number of sites > 30% of examined surfaces13 were included 
in the study. 
 
Blood Sample Collection: 
5 ml of peripheral blood was obtained by direct venipuncture (21 gauge) using 
disposable syringe from the antecubital vein of each subject after skin preparation.The 
samples were immediately transferred into EDTA containing vacutainer tubes. The 
vacutainer tubes were kept in thermos ice box and transferred immediately to the 
Department of Genetics, University of Madras, Chennai, where the buffy coat was 
separated and  stored at –20°C until isolation of DNA was done. 
 
DNA Isolation and Purification: 
 The phenol chloroform method of DNA isolation was used in this study. This 
frequently used method for DNA isolation removes proteins and other cellular 
components from nucleic acids, resulting in relatively pure DNA preparations.  
 
26 
 
I. Principle: 
 The concept of isolation of DNA is that all the other components of the cell and 
chromatin are removed using suitable methods to leave behind the DNA. In general the 
isolation of DNA from mammalian tissues follow four different steps. 
 1. Lysis of cells with a detergent like sodium dodecyl sulphate (SDS). 
 2. Digestion of proteins with enzymes (Proteinase – K). 
 3. Extraction of DNA by phenol chloroform method.  
 4. Precipitation of DNA with isopropyl alcohol or 100% ethanol. 
 
II. Reagents and their Functions 
1. RBC Lysis Buffer 
 Ammonium chloride – 155mM (8.29g) 
 EDTA      – 0.1mM (1.00g) 
 NaHCO3     – 12mM  (0.034g) 
 Adjust pH to 7.4 with 1M HCl or NaOH, make upto 1000ml with distilled water. 
Autoclave and store at room temperature.  
The RBC lysis buffer is used to lyse the erythrocytes. 
 
2. SE Buffer/WBC Lysis Buffer 
 Na2EDTA – 25mM   (8.41g) 
 NaCl         – 200mM (11.69g) 
  Adjust pH to 8.0 with 1M NaOH, make upto 1000ml with distilled water, 
autoclave and store at room temperature. 
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3. Proteinase K (10 mg/ml) 
 Proteinase K  - 100 mg 
 TE   - 10 ml 
 Dissolve 100mg Proteinase K in 10ml TE for 30min at room temperature and 
store it at -20°C. Proteinase K is the enzyme commonly employed for digestion of 
proteins. It is a highly active protease purified from the mold Tritirachium album. The 
digestion with proteinase K is usually carried out in presence of EDTA because EDTA 
inhibits the action of Mg2+ ion dependent nucleases which otherwise can digest the 
DNA. 
 
4. Sodium dodecyl sulphate (SDS) 10% 
 SDS - 10 gram 
 Add water to make up to 100 ml, stir on a magnetic stirrer, filter and store at 
room temperature. 
 
 SDS is the commonly used detergent for DNA isolation. It ruptures the cell wall 
and nuclear membranes to release the contents. Furthermore, it also denatures proteins 
present in the sample. 
 
5. Phenol (Saturated, pH 8) 
 Phenol is used to extract the DNA from the solution. In alkaline pH it extracts 
the DNA to the aqueous phase, which is collected for further purification. This will 
prevent the contamination of DNA with RNAs. In neutral or acidic pH phenol extracts 
RNA to aqueous phase. Hence, the pH of phenol is very important for this step. The pH 
of phenol should be maintained above 7.8 as all eukaryotic RNA with poly-A tails 
dissolve in alkaline phenol but in the acid range the DNA will partition into organic 
phase.  
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6. Phenol: Chloroform : Isoamyl alcohol mixture 
 To prepare Phenol: Chloroform: Isoamyl alcohol mixture mix 25 parts of Phenol, 
24 parts of Chloroform and 1 part of Isoamyl alcohol. 
 
 The denaturation of proteins is mainly achieved through the activity of 
chloroform. It causes surface denaturation of proteins and also helps in removal of fats 
from the sample. Chloroform also eliminates any traces of phenol as phenol can cause 
phosphodiester breakage. Mixture of phenol and chloroform is also useful for the 
removal of protein from nucleic acid samples. 
 
 Because of the presence of proteins in the solution, the chance of foaming is 
more for the solution at the time of phenol: chloroform extraction. The action of isoamyl 
alcohol is to reduce the foaming and to maintain the stability of layers after 
centrifugation of deproteinised solution. 
 
7. Isopropyl Alcohol 
 The action of isopropyl alcohol is to precipitate the DNA leaving RNA and 
polysaccharides in the solution.  
 
8. 70% Ethanol 
 Ethanol  - 70 ml 
 Distilled water  - 30 ml 
 It removes residual salt and moisture in the precipitated DNA. 
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9. Tris-EDTA (TE) Buffer (pH - 8.0) 
 Tris base - 1.2114 gram 
 EDTA  - 0.0372 gram 
 Dissolve in 900 ml distilled water and adjust the pH to 8. Make up the volume to 
1000 ml. Filter, autoclave and store at 4oC. Ideal buffer to store the DNA. 
 
iii. Procedure 
 5ml of whole blood was spun at 3500rpm for 20min at 25°C. Buffy coat was 
removed carefully and transfered to a new 2.0 ml eppendorf  tube. 1ml of 1xRBC lysis 
buffer was added to the buffy coat, vortexed, mixed well and incubated for 15 min at 
37°C followed by a spin at 3500rpm for 15 min at room temperature. The supernatant 
was discarded, the pellet was dislodged and washed 2 or 3 times with 1ml RBC lysis 
buffer (repeat of step 2) until a half white pellet appears. The pellet was then dislodged 
by tapping to which 500μl of SE (WBC lysis) buffer, 5μl ProteinaseK (final 
concentration 50μg/ml) and 25μl (final concentration 0.5%) 10% SDS was added and 
incubated in water bath at 37°C for overnight or 55°C for 3 hours.  Equal volume of 
Phenol: Chloroform: Isoamylalcohol (25:24:1) to the lysate was added and intensely 
mixed well by inverting the tube until it turns to milky white in colour. The samples 
were spun at 10,000 rpm for 15min at room temperature. The upper aqueous phase alone 
was carefully collected  with the help of wide bore tips without disturbing the other 
layers and transferred  to a new tube. To this aqueous phase 2.5 volumes of chilled 
absolute ethanol was added and the tubes were inverted gently for several times. The 
DNA will be visible like a thread and will assume the shape of a cotton ball. The DNA 
was transferred to an eppendorf tube already containing 1ml of 70% ethanol and spun at 
12,000g for 10 min at 4°C. The Ethanol was discarded and the pellet is air-dried in a 
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sterile place for 3 hours to remove any trace of residual ethanol. Appropriate amount of 
1x TE was added according to the size of the pellet, allowed to dissolve and stored at 
4°C. 
 
Quality Check & Quantification of DNA 
 The integrity of the DNA was assessed by running it in 0.7% Agarose gel. 
Further the quantification and quality check of DNA was performed by subjecting the 
DNA to spectrophotometry. 
 
I. Principle 
 The concept of quality check of DNA is to find out the purity of the extracted 
DNA. The extracted DNA may contain impurities like phenol, proteins and others. The 
integrity of the DNA is checked by agarose gel electrophoresis. 
 
 When the DNA is mixed with loading dye and run electrophoretically on 0.7% 
agarose gel in TAE buffer, the good high molecular weight DNA will appear as sharp 
band without smearing. 
 
II. Reagents  
1) TAE buffer (10x) 
 Tris base   - 48.4 gram 
 Glacial acetic acid  - 11.42 ml 
 0.5 M EDTA (pH 8.0) - 20 ml 
 Distilled water to make up to 1000 ml 
 Autoclave and store at room temperature. 
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2. Gel loading dye – Type III (6x) 
 Bromophenol blue   - 0.25% (w/v) 
 Xylene cyanol FF  - 0.25% (w/v) 
 Glycerol in water  - 30% (v/v) 
 Stir well  and store at 4oC. 
 
3. Ethidium bromide 
 Ethidium bromide  - 10 mg 
 Distilled water   - 1 ml 
 Mix well  to ensure that the dye has dissolved completely. Wrap the tube in 
aluminum foil and store at room temperature. 
 
III. Procedure for Agarose Gel Electrophoresis 
1. 0.7% Agarose Gel preparation 
•  0.7 gram of agarose weighed and transferred into a 250 ml conical flask. 
• 100 ml of 0.5x TAE buffer was added to it, stirred well and melted on a 
magnetic stirrer cum hot plate until the agarose dissolves completely. 
• The appropriate sized gel tray and comb was washed and wiped with 70% 
Ethanol. The gel tray was placed inside the casting unit. The comb was placed 
on the gel tray and left on an even surface. 
• After the agarose cools down to hand bearing temperature, 5 μl of ethidium 
bromide was added and mixed well. It was poured on the gel tray and allowed 
to polymerize. After polymerization the comb is removed gently. 
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2. Preparation of sample and loading 
• The gel tray was removed from the casting unit and the tray placed in the 
electrophoresis tank. 
• 0.5x TAE buffer was poured into the tank until the gel gets immersed.  
• 2 μl of each DNA sample was taken and mixed with 2μl of 6x loading dye and 
8ml of sterile double distilled water. 
• The DNA samples were loaded into the wells. 
•  The electrodes were connected. 
• The power was switched ON, set at 100 V. 
• As the DNA is negatively charged, it will migrate towards the anode. 
 
3. Visualizing the DNA 
• When the bromophenol blue dye was in the middle of the gel, the power was 
switched OFF. 
• The gel was taken to the transilluminator and observed under UV and 
documented. 
• The good high molecular weight DNA will appear as sharp band without 
smearing.  
 
IV. Procedure for Spectrophotometry 
  The nucleic acid sample was analysed at 260nm and 280nm by using 
Nanodrop Spectrophotometer (Thermo scientific, Germany). The concentration and 
purity of the sample was analysed using the following formula, 
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Concentration of DNA: 
  Concentration of double stranded DNA sample (μg/μl) = A260 x 50 
 
Purity of DNA: 
Pure DNA = A260 /A280 ≥ 1.8 
< 1.8 indicates protein and phenol contamination 
>2.0 indicates the possible contamination with RNA 
Figure 1: Nanodrop spectrophotometer window of a representative sample 
showing the absorption spectra of DNA (peaks at 260nm) 
 
 
DNA Dilution: 
 After confirmation for the presence of genomic DNA in the sample and 
quantification, the sample has to be diluted with autoclaved sterile double distilled water, 
to make it amenable to be used in polymerase chain reaction. The amount of DNA 
needed for PCR is 50-100 ng of DNA for a 20 μl reaction mixture. 
  
  Once a working DNA sample has been prepared, it was run in 1% agarose gel 
electrophoresis, observed under UV and documented. 
 
34 
 
POLYMERASE CHAIN REACTION 
I. Principle 
 PCR entails enzymatic amplification of specific DNA sequences using two 
oligonucleotide primers that flank the DNA segment to be amplified. The rapid 
production of large quantities of a specific DNA sequence took a leap forward with the 
development of the PCR. The PCR requires two nucleotide oligomers (Primers) that 
hybridize to the complimentary DNA strands in a region of interest. The method relies 
on thermal cycling, consisting of cycles of repeated heating and cooling of the reaction 
for DNA melting and enzymatic replication of the DNA. 
 
II. Reagents  
1. 10x PCR buffer  
2. 25 mM MgCl2 
3. 2.5mM dNTP Mix 
4. Forward Primer (Sigma Aldrich, USA) 
 The sequence is 
 5'- GCCCTCTTACCTGAATTTTGGTAGCCCTC-3' 
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Figure 2: Oligo Calculator – A bioinformatic tool that analyses the melting 
temperature and other details of Primer sequences:   
Shown below is the Forward Primer 
Enter Oligo Sequence in Box 
GCCCTCTTACCTGAATTTTGGTAGC
CCTC
Length 29  Melting Temperature (Tm) 63 °C  
52 %GC content Molecular Weight: 8767 daltons (g/M) 
OD of 1 is equal to 3557 picoMolar. 
 
 5).Reverse primer (Sigma Aldrich, USA) 
 The sequence is  
 5' - AGATTTACTTTTCAGTGGAACAGGAGTCC - 3' 
 
 
Figure 3: Oligo Calculator – A bioinformatic tool that analyses the melting 
temperature and other details of Primer sequences:  Shown below is the Reverse 
Primer 
Enter Oligo Sequence in Box 
AGATTTACTTTTCAGTGGAACAGGAG
TCC
Length 29  Melting Temperature (Tm) 59 °C  
41 %GC content Molecular Weight: 8926 daltons (g/M) 
OD of 1 is equal to 3117 picoMolar. 
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Preparation of the primer:  
The primer is obtained as lyophilized powder and is reconstituted in appropriate volume 
of sterile triple glass distilled water to a concentration of 100μM. A working stock of 
2micro Mole primer is prepared and stored at -20°C 
 The Primers were adapted from Folwaczny M et al., 200521. 
Amplicon size: 171bp 
 
Figure 4: In-Silico PCR showing the region of DNA to which the primer binds and 
amplifies (UCSC Genome Bioinformatics Database) 
 
  UCSC In-Silico PCR 
  
>chr11:112035360-112035530 171bp 
GCCCTCTTACCTGAATTTTGGTATCCCTC 
AGATTTACTTTTCAGTGGAACAGGAGTCC 
GCCCTCTTACCTGAATTTTGGTATCCCTCtccccaagcttactttctgtt 
gcagaaagtgtaaaaattattaaataaaattctaatgatggtatccgtgt 
ggcttgcatctgatacagcagataaagaagttttatgaaaatGGACTCCT 
GTTCCACTGAAAAGTAAATCT 
 
 
 
 
 6)Taq DNA polymerase (Applied Biosystems, USA) 
 Taq DNA polymerase is a highly thermostable DNA polymerase of a 
thermophilic bacterium Thermus aquaticus. Taq DNA polymerase catalyzes 5'→3' 
synthesis of DNA.   
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7. PROCEDURE 
• 2μl of genomic DNA (100ngμl) is pipetted directly to the bottom of the labelled PCR 
tubes.  
• Preparation of master mix: A master mix of all the components of PCR except the 
genomic DNA was prepared as follows: 
Stock 
Concentration 
Contents Quantity
Final 
Concentration (20μl) 
10X PCR Buffer 2.0μl 1X 
25mM MgCl2 2.0μl 2.5mM 
2.5mM dNTP mix 0.8μl 50μM 
2μM Forward Primer 0.8μl 80nM 
2μM Reverse Primer 0.8μl 80nM 
5U/μl Taq DNA Pol 0.1μl 0.25U/10μl 
 Distilled water     11.5μl  
 Total 18.0 μl  
100ng/μl Genomic DNA 2.0μl 100ng/10μl 
 
Thermal Cycle Protocol 
• The PCR mix was added into the sterile 0.2ml PCR tube and the following thermal 
cycle conditions were programmed in GeneAMP® PCR System 9700-Applied 
Biosystems, USA. 
 
. 
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Figure 5: PCR thermal cycle. Figure depicting the temperature condition and 
cycles during different phases of PCR.
 
 
After the programme is over, the samples were tested for amplification by 2% agarose 
gel electrophoresis and visualized with ethidium bromide. 
 The correct polymerase chain reaction product is  171 bp long. 
 
Restriction Fragment Length Polymorphism (RFLP) 
I. Principle 
 In this method, DNA sequence variation is identified by amplification of the 
region using polymerase chain reaction followed by digestion of the amplified product 
with a restriction endonuclease known to be capable of distinguishing the polymorphic 
patterns. The restriction fragments vary in size and can be revealed as different bands on 
gel electrophoresis.  
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II. Reagents  
1. 10x Nuclear Extract Buffer 4(NE Buffer) 
50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH 7.9.  
2. Bovine serum Albumin (BSA) 
3. MseI (New England Biolabs Inc., Beverly, MA, USA) 
4.  This is the restriction endonuclease can digest the AA but not the AC or 
CC genotype.  
 
 
iii. Restriction Endonuclease Digestion Procedure 
        One Sample 
1. PCR product    - 10 μl 
2. 10x NE buffer    -   2 μl 
3. 10x Bovine serum albumin  -   2 μl 
4. MseI (10 units/ml)   - 0.1 μl 
5. Triple glass distilled water  - 5.9 μl  
   Total   - 20 μl 
• Pipette PCR product separately to each labelled tube and prepare master mix of 
the remaining items for the required number of samples. 
• Dispense 10 μl of master mix into each tube containing PCR product.  
• Spin the tubes briefly to collect the contents at the bottom and incubate at 37oC 
overnight in a water bath. 
• Inactivate the enzyme by incubating at 65oC for 20 mins. 
• Resolve the fragments by electrophoresis using 2% agarose and visualise in a 
UV transilluminator after staining with ethidium bromide.  
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Figure 6: In-Silico Analysis of RFLP: 
Wild type Sequence digested with: MseI 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The DNA sequence of the site which is restricted by MseI 
 
 
 
       Fragment sizes when restricted 
with MseI 
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Figure 8: In-Silico Gel showing the restriction fragments when run in 2% Gel 
 
 
Custom Digest
unnamed sequence - digested with: MseI 
 
Gel Type: 
0.7% agarose  
Marker: 
none
 
DNA Type: 
Unmethylated
 
L= 102 mm  
 
The virtual gel was generated by New England Biolabs Virtual Gel Bioinformatics 
tool 
 
       Source: NEB cutter V.2 
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ARMAMENTARIUM 
 
For Periodontal Examination and Blood Sampling 
• Mouth mirror 
• Williams   periodontal probe 
• Tweezer 
• Sterile gauze  
• Mask  
• Head cap 
• Gloves 
• 5ml disposable syringe 
• EDTA containing vaccutainer  
 
For DNA Isolation 
• Centrifuge tubes – 15ml 
• Centrifuge machine 
• Wide bore Pasteur pipettes  
• Micropipette 
• TKM 1 (Low salt buffer) 
• Igepal CA – 630 
• TKM2 
• (10 % SDS) 
• 6M sodium chloride 
• Tris-EDTA buffer (TE buffer) 
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• Iso propyl alcohol 
• 70% ethanol 
• Tris EDTA buffer 
• Centrifuge – Remi 
• Vortexer  
• Water bath incubator 
• Refrigerated centrifuge 
          
    For Electrophoresis 
• Agarose  
• 10x TAE buffer  
• Microwave oven 
• Electrophoresis tank with power pack 
• Electrophoresis gel tray 
• Gel loading loading dye 
• Micropipette 
• Ethidium bromide 
• U – V light transilluminator 
 
For PCR 
• 0.5 ml eppendorf tube 
• Taq polymerase 
• Forward primer 
• Reverse primer 
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• dNTP 
• Mgcl2 
• KCl buffer 
• Template DNA 
• Thermalcycler 
• Nanocentrifuge 
• 100 bp DNA ladder 
• TGDW  
 
For RFLP 
• PCR product 
• Restriction Endonuclease enzyme (MseI)  
• Buffer  
• TGDW  
• Water Bath Incubator 
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Photograph 4: Collected samples  
 
 
Photograph 5: Control Group – HealthyPeriodontium 
 
 
Photograph 6: Study group-Chronic Periodontitis 
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Photograph 7: Centrifuge 
      
  
Photograph 8: Refrigerated Centrifuge 
     
 
Photograph 9: Water Bath 
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Photograph 10: Vortex Mixer 
 
 
Photograph 11: Reagents for DNA Isolation and Purification 
 
 
Photograph 12: Isolated DNA 
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Photograph 13: Gel tray and Gel Comb with Agarose 
 
 
Photograph 14: Electrophoresis Tank 
 
 
Photograph 15: PCR hood 
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Photograph 16: UV Transilluminator 
 
 
Photograph 17: Microcentrifuge 
 
 
Photograph 18: PCR Thermal Cycler 
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STATISTICAL ANALYSIS 
 
  Around 200 samples of Tamil speaking Dravidians were selected from the  out 
patient  wing of  Department of Periodontology, Tamilnadu Government Dental 
College,Chennai. Based on the AAP classification system and percentage of number 
of involved sites. The groups were divided into control and study group. 181 samples 
were included  (n=100 for control group and n=81 for study group) for PCR and 
RFLP analysis after checking the DNA quality and quantity based on UV 
spectrometric analysis. The study design was devised based on case control model.  
Those 181 RFLP digested product was categorized into three genotypes   namely CA, 
AA and CC for control and study group separately.  Age, gender, gingival bleeding 
index and plaque  index were included in master chart for control and study group. 
Further samples with smoking habit in the study group are noted separately. 
 
  It is supposed that age, gender and smoking could act as confounders 
influencing disease outcome37. These factors are need to be corrected or adjusted to 
really associate the effect of single nucleotide polymorphism in IL-18   coding region. 
Hence a multivariate analysis model was adopted to adjust the covariates assuming 
that C or A allele act either in productive or destructive manner. But further statistical 
analysis revealed no significant difference in distribution of alleles (C or A) or 
genotypes (CC, CA and AA) among the total study population (includes study and 
control group). 
 
  As there was no association established between the SNP in IL-18 coding 
region of our interest. It is unnecessary  to adjust the effect of covariates on disease 
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outcome among total study population. So multivariate analysis model was dropped 
out. Hence usual statistical tools were used in this study 
 
  The statistical package SPSS PC + (Statistical Package for Social Science, 
Version 18) was used for statistical analysis. 
  
  Analysis of variance (ANOVA) followed by Tukey – HSD test was the 
technique used in this study to compare the mean values between control, study group 
A and B. ANOVA is used to test equality of means, when more than two populations 
are considered. 
  
A set of N = Cr observations classified in one direction may be represented as 
follows: 
   X1r X2r Xcr 
Mean =  
   X1 X2 Xc 
 
   X1  + X2 + ....... Xc 
X =  
    C 
 
Then 
 `Between column' sum of squares : SSC =  ( )2∑ −
j
j XX  
 `Within column' sum of squares : SSE =  ( )2∑∑ −
j
jij
i
XX  
Total  sum of squares : SST =  ( )2∑∑ − jXX j  
SST = SSC + SSE 
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Anova Table 
 
Source of 
Variation 
Sum of 
squares 
Degrees of 
freedom 
Mean sum of 
squares 
Variance ratio
Between 
columns 
SSC C-1     SSC 
MSC = 
    C - 1 
 MSC 
F = 
 MSE 
Within 
Columns 
SSE N-C     SSE 
MSE = 
    N - 1 
 MSE 
 = 
 MSC 
Total SST N-1   
 
CHI-SQUARE TEST 
 Chi-square test with Pearson's Correlation Coefficient was employed to 
compare the proportion between cases and controls. The formula used as 
  Σ(O-E)2 
X2 =  
     E 
  where O is the observed frequency and E is the expected frequency in a cell. 
 
Pearson's correlation coefficient may be calculated as 
         ( )( )∑ −−n yyxxn 11  
 r =  
( ) ( )∑ ∑ −−n n yynxxn 1 212 11  
 
Regression is calculated as 
 y = a0 + a1x + ε 
Where  a0 = Intercept 
  a1 = Slope 
In the present study P value < 0.05 was considered as the level of significance. 
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ONEWAY ANOVA 
In a one-way ANOVA, the F statistic tests whether the treatment effects are all 
equal, i.e. that there are no differences among the means of the J groups. A significant 
F value indicates that there are differences in the means, but it does not tell you where 
those differences are, e.g. group 1’s mean might be different than group 2’s mean but 
not different from group 3’s mean.  
 
To isolate where the differences are, you could do a series of pairwise T-tests. 
The problem with this is that the significance levels can be misleading. For example, 
if you have 7 groups, there will be 21 pairwise comparisons of means; if using the .05 
level of significance, you would expect at least one statistically significant difference 
even if no differences exist.  
 
Therefore, various methods have been developed for doing multiple 
comparisons of group means. In SPSS, one way to accomplish this is via the use of 
the /POSTHOC parameter on the One-way command. We’ll present the SPSS output 
and then explain what the different parts mean. 
 
MEAN DIFFERENCE 
• This column gives the difference in the means of the 2 groups 
• STANDARD ERROR.  
• In a One-way Anova, the standard error of the difference between the two 
means of groups i and j is  
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SIGNIFICANCE: 
This column gives you the significance of the difference under the multiple 
comparison method being used. To understand this, we need explain following 
method being used and what their rationale is. 
 
When the decision from the One-Way Analysis of Variance is to reject the 
null hypothesis, it means that at least one of the means isn't the same as the other 
means. What we need is a way to figure out where the differences lie, not just that 
there is a difference.  
 
This is where the Tukey tests come into play. They will help us analyze pairs 
of means to see if there is a difference much like the difference of two means covered 
earlier. 
 
The formulas refer to mean i and mean j. The values of i and j vary, and the 
total number of tests will be equal to a combination of k objects, 2 at a time C(k,2), 
where k is the number of samples. 
 
INDEPENDENT t TEST 
  The independent t-test, as we have already mentioned is used when we wish to 
compare the statistical significance of a possible difference between the means of two 
groups on some independent variable and the two groups are independent of one 
another. 
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The formula for the independent t-test is 
,  
where 
is the mean for group 1, 
is the mean for group 2, 
is the sum of squares for group 1, 
is the sum of squares for group 2, 
n1 is the number of subjects in group 1, and 
n2 is the number of subjects in group 2. 
 
  The sum of squares is a new way of looking at variance. It gives us an 
indication of how spread out the scores in a sample are. The t-value we are finding is 
the difference between the two means divided by their sum of squares and taking the 
degrees of freedom into consideration. 
 
and 
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  We can see that each sum of squares is the sum of the squared scores in the 
sample minus the sum of the scores quantity squared divided by the size of the sample 
(n). 
So to calculate the independent-t value we need to know: 
1. The mean for sample or group 1  
2. The mean for sample or group 2  
3. The summation X and summation X squared for group 1  
4. The summation X and summation X squared for group 2  
5. The sample size for group 1 (n1)  
6. The sample size for group 2 (n2)  
We also need to know the degrees of freedom for the independent t-test which is: 
. 
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RESULTS 
Tables -1. Shows percentage of control and study population among total sample size 
we infer that the percentage of control population among total sample size, 55.2% and 
percentage of study population among total sample size, 44.8% 
Tables -2. Shows the percentage of different genotypes among total sample size we 
infer that the percentage of AA genotypes among total sample size, 7.7% percentage 
of CA genotypes among total sample size, 42.0% and percentage of CC genotypes 
among total sample size 50.3%. 
Tables-3 Shows the Mean, SD values of plaque index and gingival bleeding index for 
different genotypes among control and study group the inference as follows 
A. Plaque Index for Control group 
i. In AA genotype the Mean and SD for plaque index, 0.69% and 0.20% 
respectively. 
ii. In CA genotype the Mean and SD for plaque index, 0.76% and 0.18% 
respectively. 
iii. In CC genotype the Mean and SD for plaque index, 0.81% and 0.17% 
respectively. 
B. Gingival Bleeding Index for control group 
i. In AA genotype the Mean and SD for bleeding index, 2.89% and 1.79% 
respectively. 
ii. In CA genotype the Mean and SD for bleeding index, 2.86% and 2.31% 
respectively. 
iii. In CC genotype the Mean and SD for bleeding index, 2.87% and 1.74% 
respectively. 
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A. Plaque Index for study group 
i. In AA genotype the Mean and SD for plaque index, 0.40% and 0.15% 
respectively. 
ii. In CA genotype the Mean and SD for plaque index, 0.41% and 0.07% 
respectively. 
iii. In CC genotype the Mean and SD for plaque index, 0.38% and 0.06% 
respectively. 
B. Gingival Bleeding Index for Study group 
i. In AA genotype the Mean and SD for bleeding index, 10.03% and 3.79% 
respectively. 
ii. In CA genotype the Mean and SD for bleeding index, 5.96% and 1.05% 
respectively. 
iii. In CC genotype the Mean and SD for bleeding index, 5.37% and 0.83% 
respectively. 
Table-4 Shows the difference between control and study group for PlI, GBI among all 
the genotypes we infer that the difference between control and study group for                
PlI, GBI among all the genotypes is significant as the p value is less than 0.05. 
Table-5 Shows the one way  analysis from which we infer that  
A. For control group  
i. Mean and SD for GBI  in genotype AA   is 2.89 and 1.79  
ii. Mean and SD for GBI in genotype CA   is 2.86 and 2.31 
iii. Mean and SD for GBI  in genotype CC   is 2.87 and 1.74  
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B. For study group  
i. Mean and SD for GBI  in genotype AA   is 79.26 and 10.03  
ii. Mean and SD for GBI in genotype CA   is 79.13 and 5.96 
iii. Mean and SD for GBI in genotype CC   is 77.49 and 5.37  
Table:6 Show the difference for GBI, within the samples of all three genotypes and 
between the three genotypes separately for control and study group we infer that the 
difference for GBI, within the samples of all three genotypes and between the samples 
of three genotype for control and study group is insignificant as the p value is greater 
than 0.05. 
Tables: 7 shows the distribution of A and C alleles among control and study group we 
infer that. 
i. Total no of A allele in control group 58 
ii. Total no of A allele in study group 46 
iii. Total no of C allele in control group 142 
iv. Total no of C allele in study group 116 
Tables: 8 Shows Chi-square test for genotype distribution  which is insignificant 
between control study group. 
 
Tables: 9 Shows the Chi-square test for allele frequency  we infer that the table shows 
percentage distribution and allele frequency for A and C allele among control and 
study group is insignificant as the p values is greater than 0.05. This implies neither of 
the allele A and C is predominately distributed among control and study group. 
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Tables: 10 Shows the Mean and SD of all the genotypes for samples in study group 
with and without smoking habit we may infer as follows  
A. In samples with smoking habit  
i. The Mean value for PlI and GBI in CA genotypes are 1.80 and 76.33 
respectively  
ii. The Mean value for PlI and GBI in CC genotypes are 1.59 and 76.22 
respectively  
iii. No AA genotyped samples were found in samples with smoking habit  
B. In samples without smoking habit  
i. The Mean value for PlI and GBI in AA genotypes are 1.69 and 79.26 
respectively  
ii. The Mean value for PlI and GBI in CA genotypes are 1.67 and 79.32 
respectively  
iii. The Mean value for PlI and GBI in CC genotypes are 1.64 and 78.12 
respectively  
Table 11 Shows the significance of difference for PlI and GBI among all the 
genotypes of study group that involves samples with and without smoking habit. We 
infer that there is no significant difference for PlI and GBI among all the genotypes of 
study group that involves samples with and without smoking habit 
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Photograph 25-29 shows the electrophoresis result of PCR product 171bp. Lane 
1,20,35 are positive control – standard 100 bp DNA ladder. 
Photograph 30-34 shows electrophoresis result of RFLP product for all genotypes   
CA,CC AND AA  in control and study group we infer that 
• A thin uncut band along with restricted 171 bp as  101 and 70 –for CA 
genotype 
• A thick uncut band for 171bp -for CC genotype 
• Restricted site for both the alleles for 171 bp as 101bp and 71bp for –AA 
genotype. 
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Tables 1: Percentage of control and study  
population among total sample size 
 
 
 
 
Group 
N % 
Control 100 55.2
Study 81 44.8
Total 181 100.0
 
 
Tables 2: Percentage of different  
genotypes among total sample size 
 
 
 N % 
AA 14 7.7
CA 76 42.0
CC 91 50.3
Total 181 100.0
 
 
Tables 3: Mean, SD values of plaque index and GBI for different genotypes 
among control and study group. 
 
 
Group 
Control Study 
Genotype Mean SD SE N Mean SD SE N 
AA 
PlI .69 .20 .08 7 1.69 .40 .15 7 
GBI 2.89 1.79 .68 7 79.26 10.03 3.79 7 
CA 
PlI .76 .18 .03 44 1.67 .41 .07 32 
GBI 2.86 2.31 .35 44 79.13 5.96 1.05 32 
CC 
PlI .81 .17 .02 49 1.63 .38 .06 42 
GBI 2.87 1.74 .25 49 77.49 5.37 .83 42 
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Table 4: Difference between control and study group  
for PlI,GBI among all the genotypes. 
T-Test 
Independent Samples Test  
 
 
Levene's Test for 
Equality of Variances t-test for Equality of Means 
F Sig. t df Sig.  (2-tailed)Genotype 
 
AA 
PlI 15.150 .002 -5.970 8.875 .000
GBI 4.372 .058 -19.827 12 .000
AC 
PlI 36.254 .000 -11.698 40.047 .000
GBI 26.743 .000 -68.697 37.809 .000
CC 
PlI 31.593 .000 -12.945 55.616 .000
GBI 28.616 .000 -86.220 48.335 .000
 
 
Table 5:  One way analysis 
Group Mean SD SE N 
Control Gene 
AA GBI 2.89 1.79 .68 7 
AC GBI 2.86 2.31 .35 44 
CC GBI 2.87 1.74 .25 49 
Study Gene 
AA GBI 79.26 10.03 3.79 7 
AC GBI 79.13 5.96 1.05 32 
CC GBI 77.49 5.37 .83 42 
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Tables 9: Chi-square test for allele frequency 
 
Control (%) Study group (%) x2 p value 
A 58 (29) 46 (39.7) 0.005 0.932 
C 142 (71) 116 (71.34) 
 
Tables 10: Mean and SD of all the genotypes for samples in study group with and 
without smoking habit. 
 
 
Group 
Study Group 
Smoking Habit 
Yes No 
Plaque Index Bleeding Index Plaque Index Bleeding Index 
Gene Mean N Mean N Mean N Mean N 
AA . . 1.69 7 79.26 7 
CA 1.80 2 76.33 2 1.67 30 79.32 30 
CC 1.59 14 76.22 14 1.64 28 78.12 28 
 
 
Table 11: Significance of difference for PlI and GBI among all the genotypes of 
study group that involves samples with and without smoking habit. 
T-Test  
Independent Samples Test(a)  
 
 
Levene's Test for Equality 
of Variances t-test for Equality of Means 
F Sig. T df Sig. (2-tailed)
Gene 
 
 
 
 
 
CA 
PlI 1.177 .287 .456 30 .652 
GBI 1.139 .294 -.680 30 .502 
CC 
PlI 1.450 .236 -.372 40 .712 
GBI 1.974 .168 -1.084 40 .285 
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PHOTOGRAPH FOR PCR  
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PHOTOGRAPH FOR RFLP 
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Photograph 34 
 
 
CA  AA CC 
 71 
 
DISCUSSION 
 
  Unraveling the pathophysiology of destructive periodontal disease comprises 
one of the major challenges in periodontology72. Currently, genetic factors causing 
imbalances in pro-and anti-inflammatory cytokine production along with an 
ineffective immune response against bacterial invasion were thought to increase the 
susceptibility for periodontitis6. 
 
  Among the different cytokines that are typically expressed in periodontal 
lesions specifically the level of IFN-γ was suggested to be positively correlated with 
the progression of the disease87.  A considerably higher level of IFN-gamma was 
found in aggressive periodontitis patients and in active periodontal pockets suggesting 
a destructive role for IFN- γ 24. Moreover, studies in rodents reported a significantly 
decreased bone loss for mice lacking the cytokine IFN-gamma suggesting an 
important role for IFN- γ in periodontitis associated tissue destruction6,33. IL-18 plays 
an important role in the regulation of IFN- γ production. IL-18 protein expression is 
regulated by the IL-18 promoter gene85. Two single nucleotide polymorphisms within 
the promoter region have recently been described that were suggested to impair IL-18 
expression. At position -607 the change from cytosine to adenine disrupts a binding 
site for CREB (cyclic AMP-responsive element-binding protein) and at position -137 
the change from guanine to cytosine affects the H4TF-1 (human histone H4 gene-
specific transcription factor-1) binding site82. 
 
  Upon stimulation low promoter activity was observed for A and C alleles at 
positions -607 and -137, respectively28. Consistently, it was shown that the 
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polymorphisms that have been investigated herein reach significant impact on the 
pathophysiology of various inflammatory and/or autoaggressive conditions, e.g. 
rheumatoid arthritis46, sarcoidosis82, and type 1 diabetes34. However, the functional 
influence of the polymorphisms investigated herein still remains to be proved.  
 
  The frequency of the alleles and genotypes for the IL-18 gene polymorphisms 
observed herein is consistent with previous data from other study groups46,84. The 
present study revealed no association between any of the IL-18 gene polymorphisms 
and the susceptibility for periodontitis. Both the frequencies for the alleles and the 
distribution of genotypes were almost equal among the two study groups.  It is clear 
from studies that the IL-18 molecule shares structural homology with the IL-1 
family16,26.  This  holds the value to be related to a recent  study on association of 
Single Nucleotide Gene Polymorphism at Interleukin-1b +3954, -511, and -31 in 
Chronic Periodontitis and Aggressive Periodontitis in Dravidian Ethnicity found 
association for In the Malayalam-speaking Dravidian population2.  In that study allele 
C of IL-1b +3954 appeared to be an important risk factor for chronic periodontitis. 
But in our study we find no association for C-A snp at position -607 promotor region 
of intrleukin 18 coding region considering A allele as risk allele based on the Cloning 
and mutation analysis of the human IL-18 promoter  region28. As we didn’t find SNP 
distribution for other five position of  IL-18, we may not be able to conclude that IL-
18 promotor and coding region polymorphisms are insignificant among 
periodontontitis patients. 
 
  Our study is consistent with earlier findings of a previous study21 in which the 
distribution of genotypes for the IL-18 gene polymorphism at position-607 as 
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insignificant  whose p value is 0.854. The p value of our study is 0.839, a comparable 
integer to the p value of  above mentioned study. Further  we found the percentage 
distribution of allele frequency for A and C allele among control and study group is 
statistically insignificant as the p values is greater than 0.05 (p value 0.932). This 
implies neither of the allele A and C is predominately distributed among control and 
study group. 
 
  Hence we infer that the distribution of genotypes and allele frequency for the 
IL-18 gene polymorphism at position-607 was not significantly different among 
periodontitis patients if compared with healthy control subjects in total sample of 
Tamil speaking Dravidians. As we didn’t find the association for any allele in 
periodontal health and disease, multivariate analysis model to control the confounders 
was not developed. 
 
  Considering the complex and redundant regulation of cytokine cascades that 
occurs in inflammation, it is reasonable to anticipate that polymorphisms at multiple 
genes may influence the qualitative and quantitative aspects of periodontal 
inflammation. Therefore, to determine the exact direct and epistatic (interaction 
among multiple alleles) involvement of the IL-18 gene in periodontitis, further studies 
that simultaneously examine the distribution and dynamics of genetic variation at 
many loci on the IL-18 gene are essential. Studies that combine many genetic 
variants, even with moderate effects, may substantially improve our ability to predict 
periodontitis risks and the clinical use of genetic research. 
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SUMMARY AND CONCLUSION 
 
  About 200  patients  in  the  age   group  of  30- 70  years who  attended  the  
out patient  wing of  Department of Periodontology, Tamilnadu Government Dental 
College, Chennai  during March to December of 2010  participated  in the  study . The 
patients  were divided  into  two  groups,  81 subjects  with  generalized chronic 
periodontitis and 100  periodontally healthy subjects    included as study and control 
group respectively. All were Tamil speaking Dravidians. 
 
   Plaque index, gingival bleeding index, probing depth and clinical attachment 
level. (Based on AAP-1999 classification), were used to categorize the patients to 
Control Group, Study Groups (Generalised Chronic Periodontitis). Generalised 
chronic periodontitis cases were selected based on the percentage of involved no of 
sites13.  
 Five ml of blood was drawn from antecubital vein and DNA was isolated by 
the Non-enzymatic method. The concentration of the isolated DNA was adjusted 
suitably and PCR was carried out to amplify the IL- 18 promotor region at -607 
position. Allelic variants at -607 position were identified by restriction fragment 
length polymorphism (RFLP) using MseI enzyme. Data thus collected were analysed 
statistically. 
 
  We found the percentage distribution of allele frequency for A and C allele 
among control and study group is statistically insignificant as the p values is greater 
than 0.05 (p value 0.932). This implies neither of the allele A and C is predominately 
distributed among control and study group. The study results are  in consistent with 
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earlier findings of a previous study21 in which the distribution of genotypes for the IL-
18 gene polymorphism at position-607 as insignificant  whose p value is 0.854. The p 
value of our study is 0.839 is comparable to the p value of above mentioned study. 
 
Hence the present findings indicate that the susceptibility for periodontitis is 
not influenced by the SNP at -607of IL 18 gene that have been investigated in this 
study and we find no association between them.  Herein the distribution of genotypes 
and allele among periodontitis patients and healthy control individuals was not 
significantly different for the SNP at -607of IL 18 gene.   
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